Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. - Wikidata - wikimedia - TriplyDB

Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.

Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.

http://www.wikidata.org/entity/Q34622644

about

History of the discovery of vitamin D and its active metabolites From "Kidneys Govern Bones" to Chronic Kidney Disease, Diabetes Mellitus, and Metabolic Bone Disorder: A Crosstalk between Traditional Chinese Medicine and Modern Science The serum 24,25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease.Vitamin D in Chronic Kidney Disease and Dialysis Patients.Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.Estimated GFR and circulating 24,25-dihydroxyvitamin D3 concentration: a participant-level analysis of 5 cohort studies and clinical trials.Retinoic acid suppresses parathyroid hormone (PTH) secretion and PreproPTH mRNA levels in bovine parathyroid cell culture Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure.Mechanisms of secondary hyperparathyroidism.Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial.Percutaneous ethanol injection therapy for advanced renal hyperparathyroidism in Japan: 2004 survey by the Japanese Society for Parathyroid Intervention Long-term prognosis of parathyroid function in chronic dialysis patients after PEIT-a single-centre trial.A new paradigm for the treatment of secondary hyperparathyroidism.Secondary hyperparathyroidism disease stabilization following calcimimetic therapy.Chronotherapy of high-dose active vitamin D3 in haemodialysis patients with secondary hyperparathyroidsm: a repeated dosing study.Adsorption of oxacalcitriol by polysulphone haemodialyser in patients with secondary hyperparathyroidism.PKPD modelling to predict altered disposition of 1α,25-dihydroxyvitamin D3 in mice due to dose-dependent regulation of CYP27B1 on synthesis and CYP24A1 on degradation.The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism.Sexual dysfunction in dialysis patients: does vitamin D deficiency have a role?Impaired vitamin D metabolism in CKD Mineral metabolic abnormalities and mortality in dialysis patients.Efficacy and safety of oral doxercalciferol in the management of secondary hyperparathyroidism in chronic kidney disease stage 4 Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study.Chronic renal insufficiency in infants and children.Role of vitamin D in chronic kidney disease.Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease.Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges.Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?Diseases of the parathyroid gland in chronic kidney disease.Pharmacotherapy of chronic kidney disease and mineral bone disorder.Calcitriol resistance in hemodialysis patients with secondary hyperparathyroidism.Management of secondary hyperparathyroidism: how and why?Research on kidney and mineral metabolism in Japan: past, present, and future.Genetic Variants Associated with Circulating Parathyroid Hormone.Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention.Adynamic bone disease-bone and beyond.

P2860

Q24614880-F8F950BC-342D-49B2-B729-4DA32927760E Q28079011-AD58ED38-48A9-4824-96D5-47E907E74F24 Q30524695-FEF77BB3-0FF7-41B7-8BCF-69582D9E0CA9 Q33616582-79234074-C7CB-42B1-A0E1-393671A9EEF7 Q33827370-C62BEFB9-341E-4D11-87C4-55CFB56B1D25 Q33917786-5C743D43-C189-4157-929B-459FBF961528 Q33954224-894F051B-87C0-4A67-8BC4-E0F659F50C83 Q34126080-D78A13F9-6723-489E-8AEF-B7AA3D19FA98 Q34262129-FA83F950-5CA2-433B-928B-1E8BA7F7579F Q34543837-4C74A3E0-6638-491F-90F7-1A74CBFBD7DC Q34776998-7F965D77-B9E5-4932-91D3-D2FD19CCFCC1 Q34868253-CD524E38-66B9-4DCC-A05E-EE70200969AE Q35573604-F1E6818B-3DE2-47F5-BEE1-FB5DC7958CFB Q35573606-4E787855-BBA4-41EC-8D77-A46C4A761D7F Q35573634-BCCA80FD-45DD-4DB3-B86C-63B3895B5409 Q35573653-B8DEAA4E-BB27-4E4F-8442-388C6B3E51D2 Q35825381-032C1E7B-5C64-4C6F-B9C8-24B457EC51AF Q35826473-52276B79-6B76-4758-B03A-73875A96AFA5 Q35865449-A0435518-1780-4D28-B89D-5200D47A25E5 Q35928870-0B67D53D-A02E-448B-9FF3-064BFE250CDC Q36511587-EAD33FD4-0135-423C-AF61-F14796CF60CC Q36668070-8C19D16D-CE3B-4BE8-8395-69B6AF627FA2 Q36994038-99864E0D-FC21-4F87-9E5F-0496975FB5D1 Q37091145-39D528B3-285A-4C7B-A61B-80C9045EB221 Q37099010-669BF121-430C-4112-8A78-01620DA6CB3D Q37125654-F0C934CE-97BD-409B-B3AD-5CA50963763C Q37207710-A43DBDE0-F95E-4E2F-BC20-BFC05DBBCAD8 Q37226885-F1B508C8-E067-436B-8072-1857721625E5 Q37553481-76A43635-BDB1-4865-8650-E51B30547959 Q37807991-D0540D66-E6DE-4245-B257-500526008ACF Q37891153-560DFE0F-F9D2-4C0F-A49D-ADFDB8CA2E4A Q37912038-4EFBED56-00F0-4E9B-90A8-B9211C369B81 Q37948105-CAC0D4FB-FAB9-4197-B619-F24B61C7BE55 Q38175317-A33A76A4-876E-4AB9-B001-0A96E5C258D4 Q38775426-5E3A5C15-3149-47FB-94C0-6EB005F0378B Q38779344-46F347EF-B463-443A-845F-36D0C4A3FBC1 Q38785985-26CB5FDD-7D58-460A-8DF7-1A516B0051D8 Q40305016-741467BE-3C95-4460-BBF9-89D1180CABA2 Q40318301-895B0B99-FF3A-4A0F-8BF2-9278CD52A1A0 Q40319624-9AA0724F-391E-4218-824B-AC1F9258121F

P2860

Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.

http://www.wikidata.org/entity/Q34622644

description

1984 nî lūn-bûn

@nan

1984 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1984 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

1984年の論文

@ja

1984年論文

@yue

1984年論文

@zh-hant

1984年論文

@zh-hk

1984年論文

@zh-mo

1984年論文

@zh-tw

1984年论文

@wuu

name

Marked suppression of secondar ...... calciferol in uremic patients.

@ast

Marked suppression of secondar ...... calciferol in uremic patients.

@en

Marked suppression of secondar ...... calciferol in uremic patients.

@nl

type

label

Marked suppression of secondar ...... calciferol in uremic patients.

@ast

Marked suppression of secondar ...... calciferol in uremic patients.

@en

Marked suppression of secondar ...... calciferol in uremic patients.

@nl

prefLabel

Marked suppression of secondar ...... calciferol in uremic patients.

@ast

Marked suppression of secondar ...... calciferol in uremic patients.

@en

Marked suppression of secondar ...... calciferol in uremic patients.

@nl

P1433

Q34622644-30D007B9-BD49-4256-B2BC-44BF736C4881

P1476

Q34622644-551902F0-A47D-4478-8A75-B49A85726196

P2093

Q34622644-26217079-3E1E-4077-8F04-967AF5E5497F

Q34622644-2A14B607-8601-4D24-B19A-B0D382FA16E0

Q34622644-45413E8F-D0B4-4E59-AF87-42389E7E3E98

Q34622644-8ACAEE80-76B9-401F-BDCD-E659D059473A

Q34622644-E0E38626-AB8B-4D96-9C06-598AD7F297FE

Q34622644-EF5AE861-CE3D-46BD-B65D-397A1CD59D49

P2860

Q34622644-03499548-8A43-4B48-83B5-F7C0A5F8CA20

Q34622644-210BDD89-3D0B-4A04-B645-F3D5DD6EAF0D

Q34622644-46BCB3E2-7764-43E8-90EA-33A709491640

Q34622644-620E6C4B-7B60-468A-9EFF-B46D566CE0C6

Q34622644-74C13EEA-5546-4003-A7B9-7C1E2536D51F

Q34622644-8B283F20-9467-4C20-9F7E-1347D1157652

Q34622644-9DA04D7C-1345-41D7-8BCE-C7ABC10E9CB5

Q34622644-9EFBC6C7-EE26-41C0-A650-ACB4D050A66D

Q34622644-9F3D8FF3-F8D4-4378-A3F0-0118CAE117FD

Q34622644-ADD4A633-3DF1-4AEB-994A-6C9D30DFA07C

P304

Q34622644-6B60091A-4D51-4956-811F-07E931ECB5AD

P31

Q34622644-86C3A375-531C-46BC-94FE-2D61861D24C4

P356

Q34622644-94FBDF61-FE1A-41F7-A62F-7F51706F0055

P407

Q34622644-2C2D42E1-91C6-4BEC-AE28-20640620B8F6

P433

Q34622644-B43A2E92-1DD1-4A42-8977-3CA2D77BC371

P478

Q34622644-225F4C9C-FCF0-44D0-9669-AD9E33842FF3

P577

Q34622644-56CDFE6B-8825-4195-B2DD-1254AF13C18A

P698

Q34622644-DEF928CA-FB20-49CE-8EE6-F53DE5915330

P921

Q34622644-9D69C787-57F9-43FA-8B44-C5B0EC618F06

Q34622644-E9F11553-F15F-40D7-85A5-51CD88CEA48F

P932

Q34622644-489AE86F-4CFA-4A7C-A2FD-4588850B37D4

P356

P1433

Journal of Clinical Investigation

P1476

Marked suppression of secondar ...... calciferol in uremic patients.

@en

P2093

C Weerts

http://www.w3.org/2001/XMLSchema#string

E Slatopolsky

http://www.w3.org/2001/XMLSchema#string

H Harter

http://www.w3.org/2001/XMLSchema#string

J Thielan

http://www.w3.org/2001/XMLSchema#string

K J Martin

http://www.w3.org/2001/XMLSchema#string

R Horst

http://www.w3.org/2001/XMLSchema#string

P2860

Radioreceptor assay for 1 alpha,25-dihydroxyvitamin D3

Decrease in serum immunoreactive parathyroid hormone in rats and in parathyroid hormone secretion in vitro by 1,25-dihydroxycholecalciferol.

Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue.

Control of 25-hydroxycholecalciferol metabolism by parathyroid glands.

Metabolism in immunoreactive parathyroid hormone in the dog. The role of the kidney and the effects of chronic renal disease.

Inhibition of parathyroid hormone secretion by 25-hydroxycholecalciferol and 24,25-dihydroxycholecalciferol in the dog.

Cytoplasmic and nuclear binding components for 1alpha25-dihydroxyvitamin D3 in chick parathyroid glands.

Studies on the mechanism of action of calciferol VII. Localization of 1,25-dihydroxy-vitamin D3 in chick parathyroid glands.

Hyperparathyroidism and renal failure.

Acute actions of 1,25-dihydroxy-vitamin D3 in normal man: effect on calcium and parathyroid status.

P304

2136-2143

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI111639

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P577

1984-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

6549016

http://www.w3.org/2001/XMLSchema#string

P921

hyperparathyroidism

P932

425405

http://www.w3.org/2001/XMLSchema#string